A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond.
Level 5 - mechanism / opinion, no new human data
Narrative clinical review without systematic review methodology
PubMed 26213556 · doi:10.7573/dic.212283
What was done
This narrative clinical review summarized the mechanism of action, pharmacodynamics, pharmacokinetics, efficacy, and adverse effects of approved and emerging GLP-1 receptor agonists (exenatide, liraglutide, albiglutide, dulaglutide, and lixisenatide) for the management of type 2 diabetes.
What was found
No quantitative data or numerical findings are reported in the abstract. The abstract qualitatively reports that GLP-1 receptor agonists improve blood glucose control, weight, blood pressure, cholesterol levels, and beta-cell function by increasing insulin secretion, decreasing glucagon release, slowing gastric emptying, and increasing satiety. The most common adverse effects described are nausea, vomiting, and injection-site reactions, alongside warnings for pancreatitis and thyroid cell carcinomas.
Why it matters
This paper summarizes how GLP-1 receptor agonists serve as treatment options for patients with type 2 diabetes who have inadequate glycemic control on metformin or who cannot tolerate it.
Limits
The abstract contains no numerical effect sizes, sample sizes, or study counts, and does not specify a systematic search strategy. As a narrative review, it lacks formal bias assessment or quantitative meta-analysis of the evaluated agents.
Cited by
- supports GLP-1 receptor agonists stimulate insulin secretion upon eating to clear glucose from the blood and improve insulin sensitivity.